{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:22:08Z","timestamp":1783628528017,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Australian Commonwealth Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005205","name":"AstraZeneca Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtocrr.2026.101014","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:56:19Z","timestamp":1777996579000},"page":"101014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma"],"prefix":"10.1016","volume":"7","author":[{"given":"Peey-Sei","family":"Kok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mason","family":"Aberoumand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subotheni","family":"Thavaneswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Kansara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Corpuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert John","family":"Simes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Khoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101014_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.seminoncol.2006.11.017","article-title":"The pathology of extrapulmonary small cell carcinoma","volume":"34","author":"Frazier","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101014_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2407-9-209","article-title":"The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004","volume":"9","author":"Wong","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtocrr.2026.101014_bib3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/imj.16281","article-title":"A comparison of the outcomes of pulmonary versus extrapulmonary extensive-stage small cell carcinoma","volume":"54","author":"Chen","year":"2024","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtocrr.2026.101014_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from Caspian","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtocrr.2026.101014_bib5","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101014_bib7","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.2004.09.075","article-title":"Small-cell carcinomas of the gastrointestinal tract: a review","volume":"22","author":"Brenner","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101014_bib8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3349\/ymj.2007.48.6.1066","article-title":"Extrapulmonary small cell carcinoma of the liver: clinicopathological and immunohistochemical findings","volume":"48","author":"Choi","year":"2007","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jtocrr.2026.101014_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5694\/mja18.00227","article-title":"Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers","volume":"209","author":"Thavaneswaran","year":"2018","journal-title":"Med J Aust"},{"key":"10.1016\/j.jtocrr.2026.101014_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2026.101014_bib11","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2026.101014_bib13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41416-020-0775-0","article-title":"Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials","volume":"122","author":"Vijayvergia","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2026.101014_bib14","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/cncr.33591","article-title":"A phase II basket trial of Dual anti-CTLA-4 and anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort","volume":"127","author":"Patel","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2026.101014_bib15","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","article-title":"Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers","volume":"26","author":"Klein","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101014_bib16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s12022-022-09722-4","article-title":"Molecular subtypes of extra-pulmonary neuroendocrine carcinomas identified by the expression of neuroendocrine lineage-specific transcription factors","volume":"33","author":"Metovic","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.jtocrr.2026.101014_bib17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","article-title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms","volume":"8","author":"Serrano","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtocrr.2026.101014_bib18","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1038\/s41598-025-86237-y","article-title":"Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value","volume":"15","author":"Yin","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtocrr.2026.101014_bib19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101014_bib20","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1200\/JCO.2025.43.16_suppl.3041","article-title":"ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update","volume":"43","author":"Patel","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101014_bib21","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2026.101014_bib22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2026.101014_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:29:02Z","timestamp":1783625342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666364326000652"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101014","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101014"}}